Form 4: Pfizer CEO Bourla Acquires Phantom Stock Units

Pfizer Chairman & CEO Albert Bourla acquired 23 phantom stock units under a deferred compensation plan on June 15, 2026.

Summary

• Albert Bourla, Chairman & CEO of Pfizer Inc., acquired 23 Phantom Stock Units (SSP) on June 15, 2026.
• These units were acquired under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.
• The phantom stock units are settled in cash upon separation from service and can be transferred to an alternative investment account.
• The acquisition represents a direct beneficial ownership of these units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine executive compensation transaction rather than a significant strategic or financial event.

Positives

• The CEO's acquisition of phantom stock units indicates continued commitment and alignment with the company's long-term performance.
• The acquisition is part of a structured deferred compensation plan, suggesting a well-established executive compensation framework.

Negatives

• The filing does not contain any negative financial or operational information.

Risks

• The value of the phantom stock units is subject to the future performance of Pfizer's stock.
• Potential risks associated with executive compensation plans, such as changes in tax laws or plan regulations, could impact the ultimate value received.

Future Outlook

The future outlook for the phantom stock units is tied to the company's performance and the reporting person's separation from service, at which point they will be settled in cash.

Industry Context

StockSavvy.ai notes that insider acquisitions of equity-linked instruments, such as phantom stock units, are common within the pharmaceutical industry as a means to retain and incentivize key executives. This aligns with industry practices for long-term performance alignment.

Related Party Transactions

• The acquisition of phantom stock units by Albert Bourla, Chairman & CEO, under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan is a related party transaction.

Stakeholder Impact

• Shareholders: The transaction itself does not directly impact share price but reflects executive compensation practices.
• Employees: The plan under which these units were acquired is part of the company's broader compensation structure for executives.
• Management: Reinforces executive commitment and alignment with company performance.

Next Steps

• Settlement of phantom stock units in cash upon reporting person's separation from service.
• Potential transfer of units into an alternative investment account by the reporting person.

Key Dates

Keywords

Pfizer, PFE, Albert Bourla, Form 4, Insider Trading, Executive Compensation, Phantom Stock Units, Deferred Compensation, SEC Filing